결핵 진단 시장 규모, 점유율, 성장 및 세계 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of tuberculosis (TB) diagnostics Market

The global tuberculosis (TB) diagnostics market was valued at USD 2.40 billion in 2025 and is projected to grow to USD 2.53 billion in 2026, reaching USD 4.14 billion by 2034, registering a CAGR of 6.33% during the forecast period. North America dominated the market in 2025 with a 28.34% share, driven by advanced healthcare infrastructure, strong disease surveillance systems, and the presence of major diagnostic companies.

Tuberculosis is a highly contagious infectious disease caused by Mycobacterium tuberculosis, primarily affecting the lungs but also capable of impacting other organs such as the brain and spine. Early and accurate diagnosis is crucial for controlling disease transmission, which has significantly increased the demand for advanced TB diagnostic solutions worldwide.

Market Trends

Rise in Public-Private Partnerships

Public-private partnerships have become a major trend in the TB diagnostics market. Governments and private organizations are collaborating to improve diagnostic accessibility and efficiency. For instance, collaborations under national TB programs in countries like India have significantly strengthened diagnostic infrastructure. Additionally, partnerships such as Roche Diagnostics' collaboration with the U.S. CDC in 2023 are enhancing laboratory capacities in high-burden regions.

Shift Toward Rapid Molecular Diagnostics

The increasing adoption of rapid molecular diagnostic technologies is transforming TB detection. These tests provide faster and more accurate results compared to traditional methods, supporting early diagnosis and better disease management. Continuous product innovations, including next-generation sequencing (NGS)-based solutions, are further accelerating this trend.

Market Growth Drivers

Increasing TB Incidence Globally

The rising prevalence of tuberculosis is a major factor driving market growth. According to global health estimates, approximately 10.6 million people were diagnosed with TB in 2021, reflecting a notable increase compared to previous years. High-burden countries such as India, China, and parts of Africa are witnessing growing patient populations, boosting demand for diagnostic solutions.

Favorable Government Initiatives

Government programs and policies aimed at eliminating TB are significantly contributing to market expansion. Initiatives such as India's Pradhan Mantri TB Mukt Bharat Abhiyaan and increased healthcare expenditure for TB control programs are enhancing diagnostic adoption. For example, India spent nearly USD 399.7 million on TB elimination programs in 2019-2020.

Growing Awareness and Screening Programs

Rising awareness about TB and increasing screening initiatives have led to higher diagnostic rates. Governments and healthcare organizations are focusing on early detection to reduce disease transmission, thereby supporting market growth.

Restraining Factors

Technical Limitations of Diagnostic Methods

Despite advancements, certain diagnostic techniques face limitations. Traditional methods like sputum smear microscopy have low sensitivity and may produce false-positive results, particularly in vulnerable populations. Advanced methods such as GeneXpert require stable electricity and have limited cartridge shelf life, posing challenges in low-resource settings.

Market Segmentation

By Type

The market is segmented into culture-based diagnostics, sputum smear microscopy, rapid molecular diagnostics, and others. The rapid molecular diagnostics segment dominated with a 50.60% share in 2026, driven by high accuracy, faster results, and increasing product launches. Culture-based diagnostics and microscopy continue to play a significant role, especially in cost-sensitive regions.

By End-user

The market is divided into diagnostic laboratories and hospitals. The diagnostic laboratories segment held a dominant share of 67.61% in 2026, attributed to the widespread availability of laboratory facilities and increasing reliance on lab-based TB testing. Hospitals are also expected to grow significantly due to the high volume of diagnostic procedures conducted in these settings.

Regional Insights

North America:

The region generated USD 0.68 billion in 2025 and is projected to reach USD 0.71 billion in 2026, maintaining its leading position due to strong healthcare infrastructure and high diagnostic adoption.

Europe:

Valued at USD 0.43 billion in 2025, the market is expected to grow to USD 0.45 billion in 2026, supported by government initiatives and adoption of advanced diagnostic technologies.

Asia Pacific:

The largest and fastest-growing region, with USD 0.78 billion in 2025, projected to reach USD 0.83 billion in 2026. High TB burden and improving healthcare infrastructure are key growth drivers.

Latin America & Middle East & Africa:

Latin America accounted for USD 0.24 billion in 2025, while the Middle East & Africa reached USD 0.28 billion, with steady growth expected due to increasing healthcare investments and market penetration by global players.

Competitive Landscape

The market is competitive, with key players such as F. Hoffmann-La Roche Ltd, bioMerieux SA, Abbott Laboratories, QIAGEN, Thermo Fisher Scientific Inc., and Cepheid (Danaher) leading the industry. These companies focus on product innovation, partnerships, and regulatory approvals to strengthen their market position.

Recent developments include:

• September 2023: QIAGEN donated TB diagnostic kits to Malaysia's health ministry.
• May 2022: Roche partnered with the Global Fund to enhance diagnostic infrastructure in developing regions.
• September 2022: BD launched advanced molecular diagnostic systems for TB detection.

Conclusion

The global tuberculosis diagnostics market is expected to grow steadily from USD 2.40 billion in 2025 to USD 4.14 billion by 2034, driven by rising TB incidence, increasing government initiatives, and advancements in diagnostic technologies. While technical limitations and infrastructure challenges persist, the growing adoption of rapid molecular diagnostics and expanding healthcare investments in emerging economies will create strong growth opportunities. North America will continue to lead the market, while Asia Pacific is anticipated to emerge as the fastest-growing region, shaping the future of TB diagnostics globally.

Segmentation

By Type

• Culture-based Diagnostics
• Sputum Smear Microscopy
• Rapid Molecular Diagnostics
• Others

By End-user

• Diagnostic Laboratories
• Hospitals

By Region

• North America (By Type, By End-user)
  • U.S.
  • Canada
• Europe (By Type, By End-user)
  • U.K.
  • Germany
  • France
  • Italy
  • Russia
  • Nordic
  • Rest of Europe
• Asia Pacific (By Type, By End-user)
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America (By Type, By End-user)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, By End-user)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Key Industry Developments
• 4.2. Incidence of Tuberculosis, By Key Countries
• 4.3. Impact of COVID-19 on the Market

5. Global Tuberculosis (TB) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Culture-based Diagnostics
  • 5.1.2. Sputum Smear Microscopy
  • 5.1.3. Rapid Molecular Diagnostics
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By End-user
  • 5.2.1. Diagnostic Laboratories
  • 5.2.2. Hospitals
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Tuberculosis (TB) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Culture-based Diagnostics
  • 6.1.2. Sputum Smear Microscopy
  • 6.1.3. Rapid Molecular Diagnostics
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By End-user
  • 6.2.1. Diagnostic Laboratories
  • 6.2.2. Hospitals
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Tuberculosis (TB) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Culture-based Diagnostics
  • 7.1.2. Sputum Smear Microscopy
  • 7.1.3. Rapid Molecular Diagnostics
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By End-user
  • 7.2.1. Diagnostic Laboratories
  • 7.2.2. Hospitals
• 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Russia
  • 7.3.6. Nordic
  • 7.3.7. Rest of Europe

8. Asia Pacific Tuberculosis (TB) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Culture-based Diagnostics
  • 8.1.2. Sputum Smear Microscopy
  • 8.1.3. Rapid Molecular Diagnostics
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By End-user
  • 8.2.1. Diagnostic Laboratories
  • 8.2.2. Hospitals
• 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. India
  • 8.3.4. Australia
  • 8.3.5. South Korea
  • 8.3.6. Southeast Asia
  • 8.3.7. Rest of Asia Pacific

9. Latin America Tuberculosis (TB) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Culture-based Diagnostics
  • 9.1.2. Sputum Smear Microscopy
  • 9.1.3. Rapid Molecular Diagnostics
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By End-user
  • 9.2.1. Diagnostic Laboratories
  • 9.2.2. Hospitals
• 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.3.1. Brazil
  • 9.3.2. Mexico
  • 9.3.3. Rest of Latin America

10. Middle East & Africa Tuberculosis (TB) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Culture-based Diagnostics
  • 10.1.2. Sputum Smear Microscopy
  • 10.1.3. Rapid Molecular Diagnostics
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By End-user
  • 10.2.1. Diagnostic Laboratories
  • 10.2.2. Hospitals
• 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.3.1. GCC
  • 10.3.2. South Africa
  • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2026)
• 11.2. Company Profiles
  • 11.2.1. F. Hoffmann-La Roche Ltd
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. bioMerieux SA
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. QIAGEN
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. BD
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Cepheid (Danaher)
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Thermo Fisher Scientific Inc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Abbott Laboratories
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Hologic, Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Hain Lifescience GmbH
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Oxford Immunotec USA, Inc.
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)